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BY-NC-ND license (http://creativecomAbstract Background/Purpose: The susceptibility breakpoints of cephalosporins for Entero-
bacteriaceae were revised by the Clinical and Laboratory Standards Institute (CLSI) in 2010
and 2011. The clinical outcome and susceptibility data were analyzed to evaluate the impact
of revised CLSI cefazolin breakpoints on the treatment of Escherichia coli bacteremia.
Methods: Forty-three bacteremic Escherichia coli isolates from Taichung Veterans General
Hospital, Taichung, Taiwan, during the period from January 2013 to December 2013, were
selected to analyze the minimum inhibitory concentration (MIC) distributions of cefazolin
and the correlated clinical responses to cefazolin therapy.
Results: The modal cefazolin MIC among the 43 isolates was 1 mg/mL and accounted for 18
(42%) isolates. The cumulative percentage for MICs  2 mg/mL was 79%. The conventional
dosing regimens achieved clinical cure in 33 (97%) of 34 patients with bacteremia due to E. coli
with a cefazolin MIC  2 mg/mL, in all of the six patients with a cefazolin MIC of 4 mg/mL, and
all of the three patients with a cefazolin MIC of 8 mg/mL.
Conclusion: The microbiological data support the revised CLSI breakpoints of cefazolin. The
conventional cefazolin dosing regimens can still achieve satisfactory clinical cure rates for
bacteremia of E. coli with a cefazolin MIC  2 mg/mL in patients without severe septic shock.nfectious Diseases, Taichung Veterans General Hospital, Number 1650, Section 4, Taiwan Boulevard,
(Z.-Y. Shi).
.08.017
Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
Revised CLSI cefazolin breakpoints for E coli 769Before the approval of the efficacy of cefazolin for the treatment of E. coli isolates with a ce-
fazolin MIC of 4 mg/mL, it is prudent to use cefazolin only when a high drug level can be
achieved in the infection site, such as the urinary tract.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The breakpoints of cefazolin against Enterobacteriaceae
had been in existence for >30 years, before new break-
points were revised by the Clinical and Laboratory Stan-
dards Institute (CLSI) in January 2010.1 The CLSI 2010
performance standards revised the interpretive criteria for
cephalosporins and aztreonam.1 The minimum inhibitory
concentration (MIC) breakpoints for cefazolin were
changed from susceptible,  8 mg/mL; intermediate, 16 mg/
mL; and resistant,  32 mg/mL in CLSI 20092 to susceptible,
 1 mg/mL; intermediate, 2 mg/mL; and resistant,  4 mg/
mL in CLSI 2010.1 The choice of cefazolin breakpoints
(susceptible,  1 mg/mL) was based on the conventional
dose of cefazolin (i.e., 1 g every 8 hours) according to
Monte Carlo Simulation in two pharmacokinetic studies of
cefazolin.3,4 However, the target attainment rates for 50%
T > MIC can achieve 94w100% at the dose of 2 g every 8
hours suggested that a breakpoint of susceptibility of 
2 mg/mL may be acceptable.3,4 To prevent the impact of
eliminating cefazolin as a useful agent for the treatment
and prevention of infections caused by some common
Enterobacteriaceae without a resistance mechanism, the
breakpoints of cefazolin for Enterobacteriaceae were
further revised by the CLSI in 2011 (i.e., susceptible, 
2 mg/mL; intermediate, 4 mg/mL; and resistant,  8 mg/mL,
based on a dosage regimen of 2 g every 8 hours).5,6 How-
ever, there were only a few studies describing the cefazolin
dosing regimens and the correlated clinical and/or bacte-
riological outcome.6e8 They did not provide information for
MIC data and the decision of breakpoints.6
Therefore, the aims of this study were analysis of MIC
distribution data of Escherichia coli and the impact of
revised CLSI cefazolin breakpoints on the clinical outcome
of E. coli bacteremia.
Methods
This study was approved by the Institutional Review Board
(IRB) of Taichung Veterans General Hospital, Taichung,
Taiwan (IRB number CE14247).
Bacterial isolates
During the period from January 2013 to December 2013,
506 E. coli nonduplicate isolates from blood specimens
were identified at the Microbiology Laboratory of Taichung
Veterans General Hospital. The disk diffusion method was
used for susceptibility tests of these isolates and read ac-
cording to the CLSI 2009 recommendations.2 There were320 isolates susceptible to cefazolin and 186 isolates
resistant to cefazolin (by the disk diffusion test, CLSI
2009).2
The medical records were reviewed for all of these 320
patients with bacteremia of E. coli susceptible to cefazolin
(by the disk diffusion test, CLSI 2009). Patients with E. coli
bacteremia due to cefazolin-susceptible isolates (by the
disk diffusion test, CLSI 2009) were included with the con-
ditions that cefazolin was the only beta-lactam antimicro-
bial agent administered throughout the course and used for
at least 7 days; or the empiric antimicrobial agents other
than cefazolin had not been used for longer than 2 days,
and then cefazolin was used instead for at least 7 days.
Patients with the following conditions were excluded:  18
years of age, malignancy, neutropenia, AIDS, negative
culture for E. coli at the source of infection other than the
bloodstream (Figure 1). Finally, only 43 isolates had met
these criteria and were selected for MIC study.
Susceptibility test
The MICs of cefazolin (Sigma-Aldrich, St. Louis, MO, USA)
were assessed using the broth microdilution method ac-
cording to CLSI recommendations.9 The antibiotics were
serially diluted twofold in 4 mL of cation-adjusted Mueller-
Hinton broth. The final range of antibiotic concentrations
was 0.01e256 mg/mL. The bacterial suspension was pre-
pared from actively growing bacteria in 2 mL of cation-
adjusted Mueller-Hinton broth, and diluted to a bacterial
cell density of 1  106 colony forming units/mL. To yield a
final inoculum of approximately 5  104 colony forming
units/mL, the 10 mL of bacterial suspension was then added
to the wells containing 100 mL of serially diluted antimi-
crobial agents. The MICs were read after overnight incu-
bation (16e20 hours) at 35C. The MIC breakpoints were
interpreted according to the guidelines established by the
CLSI.1,5 E. coli ATCC 25922 and Pseudomonas aeruginosa
ATCC 27853 were used as the quality control strains.
Clinical and bacteriological assessments
The following variables identified from medical records
were assessed: age, sex, shock status, source of infection,
length of hospital stay, time of defervescence after anti-
microbial treatment, clinical response, intensive care unit
(ICU) stay, and death. Shock was defined as a systolic
pressure < 90 mmHg that was unresponsive to fluid treat-
ment.10 The source of bacteremia was determined by
clinical assessment and positive growth of E. coli at the
source of infection.11 Heart failure was defined as the
clinical diagnosis of heart failure and ejection
Figure 1. Flowchart of patient enrollment. E. coli Z Escherichia coli.
770 K.-C. Wang et al.fraction  40% or evidence of abnormal left ventricular
diastolic dysfunction that can be determined by Doppler
echocardiography or cardiac catheterization.12 Renal
insufficiency was defined as glomerular filtration rate <
60 mL/min/1.73 m2 which presented > 3 months.13 Dia-
betes mellitus was defined as fasting plasma glucose 
126 mg/dL or the 2 hour plasma glucose value after a 75 g
oral glucose tolerance test  200 mg/dL.14 Immune
compromised status included chronic steroid use (daily
equivalent of 20 mg prednisone for  1 mo/y) and/or solid
organ transplantation.15
The efficacy was assessed by the clinical and bacterio-
logical response.16,17 The clinical response was evaluated
at the end of antimicrobial treatment and defined as cure,
failure, or indeterminate (a clinical assessment was not
possible for any reason). The bacteriological response was
evaluated at the 7th day after the discontinuation of anti-
microbial treatment and defined as eradication, presumed
eradication (absence of evaluable culture in a patient with
clinical cure), persistence, presumed persistence (absence
of evaluable culture in a patient with clinical failure of
treatment), or indeterminate (if bacteriological response
was not evaluable for any reason). Bacteriological success
was defined if eradication or presumed eradication were
present. Bacteriological failure was rated as persistence or
presumed persistence. The 14-day, 28-day and in-hospital
mortality rates were analyzed.Statistical analysis
Categorical variables were analyzed by the Pearson c2 test;
continuous variables were analyzed by the Student t test
and analysis of variance test. A p < 0.05 was considered
statistically significant. All statistical analyses wereperformed with SPSS version 22.0.0 for Windows (IBM corp.,
Armonk, NY, USA).
Results
A total of 43 E. coli isolates and their related infected pa-
tients were enrolled in this study. There were 2 (5%), 4 (9%),
18 (42%), 10 (23%), 6 (14%), and 3 (7%) isolates with the
cefazolin MICs of 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/
mL, 4 mg/mL, and 8 mg/mL, respectively. The modal cefa-
zolin MIC was 1 mg/mL and accounted for 18 (42%) isolates.
The cumulative percentage for cefazolin MICs  2 mg/mL
was 79%.
The clinical characteristics and outcomes of 43 patients
with E. coli bacteremia were classified into three groups,
i.e., the cefazolin MICs  2 mg/mL, 4 mg/mL, and 8 mg/mL
(Table 1). There were no statistically significant differences
in the demographic characteristics, comorbidity, length of
stay, time to defervescence, duration of therapy, and
mortality rates among the three groups. E. coli was isolated
from urinary tracts in 41 (95%) patients, and from biliary
tracts in two (5%) patients. The length of stay in hospital in
the three groups of cefazolin MICs  2 mg/mL, 4 mg/mL, and
8 mg/mL were 15.7  12.4 days, 14.3  4.8 days, and
18.0  16.6 days, respectively (p Z 0.91). The periods to
defervescence in the three groups of cefazolin MICs  2 mg/
mL, 4 mg/mL, and 8 mg/mL were 3.47  1.91 days,
3.33  2.4 days, and 3.67  2.0 days, respectively
(p Z 0.97). The duration of treatment in the three groups
of cefazolin MICs  2 mg/mL, 4 mg/mL, and 8 mg/mL were
13.4  4.4 days, 13.8  4.0 days, and 11.0  6.0 days,
respectively (pZ 0.63). The clinical cure rates in the three
groups of patients with cefazolin MICs  2 mg/mL, 4 mg/mL,
and 8 mg/mL were 97%, 100%, and 100%, respectively. The
total bacteriological success rates (eradication plus
Table 1 The demography and clinical outcomes of 43 patients with Escherichia coli bacteremia, stratified by cefazolin
minimum inhibitory concentrations (MICs).
Clinical characteristics Cefazolin MIC (mg/mL) p
 2 (n Z 34) 4 (n Z 6) 8 (n Z 3)
Age (y) 68.1  14.2 68.2  16.0 55.0  26.3 0.37
Gender 0.59
Female 28 (82) 4 (67) 2 (67)
Male 6 (18) 2 (33) 1 (33)
Source of infection
Urinary tract 33 (97) 5 (83) 3 (100) 0.31
Biliary tract 1 (3) 1 (17) 0 (0)
Comorbidity
Renal insufficiency 12 (35) 3 (50) 1 (33) 0.99
Heart failure 11 (32) 2 (33) 1 (33) 0.99
Diabetes mellitus 17 (50) 3 (50) 1 (33) 0.65
Immunosuppressive 4 (12) 0 (0) 0 (0) 0.56
Length of stay in hospital (d) 15.7  12.4 14.3  4.8 18.0  16.6 0.91
Time to defervescence (d) 3.47  1.91 3.33  2.4 3.67  2.0 0.97
Duration of therapy (d) 13.4  4.4 13.8  4.0 11.0  6.0 0.63
Shock 2 (6) 1 (17) 1 (33) 0.22
ICU stay 2 (6) 1 (17) 1 (33) 0.22
Clinical response
Cure 33 (97) 6 (100) 3 (100) 0.87
Failure 0 (0) 0 (0) 0 (0)
Indeterminate 1 (3) 0 (0) 0 (0)
Bacteriological response
Eradication 22 (64) 3 (50) 3 (100) 0.33
Presumed eradication 12 (36) 3 (50) 0 (0)
14-Day mortality 1 (3) 0 (0) 0 (0) 0.87
28-Day mortality 1 (3) 0 (0) 0 (0) 0.87
In hospital mortality 2 (6) 0 (0) 0 (0) 0.76
Data are presented as n (%) or mean  standard deviation.
ICU Z intensive care unit.
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evaluated at the 7th day after the discontinuation of anti-
microbial treatment.
The in-hospital mortality rate was 4.6% (2/43). Two pa-
tients in the group of cefazolin MIC  2 mg/mL expired
during the hospitalization. Although one patient had ach-
ieved clinical cure, she expired due to congestive heart
failure 7 days after the end of cefazolin therapy. Another
patient died from aspiration pneumonia at the 10th day ofTable 2 Cefazolin dosing regimens and the clinical cure
rates in 43 patients with Escherichia coli bacteremia.
Dosage Number of patients with clinical cure (%)
 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL
n Z 24 n Z 10 n Z 6 n Z 3
1 g every 6 h 13/13 (100) 6/6 (100) 3/3 (100) 2/2 (100)
1 g every 8 h 6/6 (100) 3/3 (100) 1/1 (100) d
1 g every 12 ha 2/3 (67) 1/1 (100) 2/2 (100) d
1 g every 24 ha 2/2 (100) e e 1/1 (100)
a 1 g every 12 hours and 1 g every 24 hours were used for
patients with impaired renal function.cefazolin therapy, although fever had subsided and the
symptoms of bacteremia had improved. Therefore, her
clinical response was regarded as indeterminate.
The conventional dosing regimens (i.e., 1 g every 8
hours, 1 g every 6 hours, and the reduced dose regimens for
impaired renal function) achieved clinical cure in 33 (97%)
of 34 patients with bacteremia due to E. coli with a cefa-
zolin MIC  2 mg/mL, in all of the six patients with a
cefazolin MIC of 4 mg/mL, and in all of the three patients
with a cefazolin MIC of 8 mg/mL (Table 2). Six patients were
treated with cefazolin 1 g every 12 hours as a result of renal
insufficiency and three patients were treated with cefazo-
lin 1 g every day due to end stage renal disease.Discussion
The small number of cases in this study is due to several
causes. First, to evaluate the bacteriological efficacy of
cefazolin for the treatment of sources of infection other
than the bloodstream, patients with negative culture of E.
coli from the primary source of infection were excluded.
Second, using potent antimicrobial agents as empiric
treatment for  3 days will affect the assessment of cefa-
zolin efficacy. Therefore, these patients were excluded
772 K.-C. Wang et al.from this study. Third, patients with severe bacteremia
could be complicated by a systemic inflammatory response,
pulmonary edema, mechanic ventilation, and ventilator-
associated pneumonia. Under these conditions, other
potent antimicrobial agents would be used by clinicians
instead of cefazolin. Therefore they were also excluded.
The patient selection bias in this retrospective study re-
flects the real-world practice. Therefore, the evaluation of
cefazolin efficacy focuses on the patient population of E.
coli bacteremia without severe septic shock in this study.
From the viewpoint of microbiological data, the modal
cefazolin MIC among the 43 isolates was 1 mg/mL and
accounted for 18 (42%) isolates. The cumulative percentage
for MIC  2 mg/mL was 79%. If the susceptibility breakpoint
of cefazolin was 1 mg/mL according to the CLSI 2010, 10
(23%) isolates with MIC of 2 mg/mL would be interpreted as
intermediate. This would not be compatible with the high
clinical cure rate in the group of patients with a cefazolin
MIC of 2 mg/mL. Setting the susceptibility breakpoints of
cefazolin as 1 mg/mL would have an impact on the choice of
cefazolin as an effective drug for the treatment and pro-
phylaxis of infections cause by Enterobacteriaceae. The
MIC distributions are similar to the results of the following
two studies. The MIC distributions of wild-type microor-
ganisms are available on the EUCAST website.18 Among 274
wild-type E. coli isolates with cefazolin MIC  8 mg/mL,
there were 37 (13.5%), 131 (47.8%), 67 (24.5%), 27 (9.8%),
and 12 (4.4%) isolates with cefazolin MICs of 0.5 mg/mL,
1 mg/mL, 2 mg/mL, 4 mg/mL, and 8 mg/mL, respectively.
The cumulative percentage for MIC  2 mg/mL was 85.8%. In
another study, the SENTRY Antimicrobial Surveillance Pro-
gram from 1997 to 2001 worldwide, 48,440 Enter-
obacteriaceae were analyzed for susceptibility.19 The
cumulative percentage for cefazolin MICs  2 mg/mL was
72.7% among the isolates with cefazolin MICs  8 mg/mL.19
The cumulative percentages of the isolates with MIC 
2 mg/mL ranged from 72.7% to 85.8%, and accounted for the
majority of isolates without a resistance mechanism in
these two previous reports and our study. These microbio-
logical data are all in agreement with the susceptible
breakpoint ( 2 mg/mL) of cefazolin MIC by CLSI 2011,
rather than that ( 1 mg/mL) by CLSI 2010.
Automated systems for antimicrobial susceptibility
testing have become more common in the clinical micro-
biology laboratories. However, there are differences be-
tween CLSI and U.S. Food and Drug Administration (FDA)
breakpoints; commercial manufacturers must use the FDA
breakpoints. For example, the current cefazolin concen-
tration range on the AST-GN69 card of Vitek 2 (bioMe´rieux,
Inc., Durham, NC, USA) is 4e64 mg/mL, which precludes an
evaluation of the current CLSI susceptible breakpoints (
2 mg/mL) for Enterobacteriaceae.20 The impact of differ-
ences between CLSI and FDA breakpoints on automated
antimicrobial susceptibility testing systems needs to be
solved by further work.
From the viewpoint of PK-PD data, the cefazolin
breakpoints by CLSI were revised in 2010 and 20111,5 based
on the Monte Carlo simulation analysis in two studies.3,4
The target attainment rates for 50% T > MIC could ach-
ieve 94w100% for the isolates with a cefazolin MIC of 1 mg/
mL and 64w83% for those of 2 mg/mL at the conventional
dose regimen of 1 g every 8 hours. The target attainmentrates could achieve 94w100% for the isolates with a cefa-
zolin MIC of 2 mg/mL at the higher dose of 2 g every 8
hours.3,4 Therefore, the interpretive criteria for cefazolin
in the CLSI 2011 were revised (susceptible,  2 mg/mL; in-
termediate, 4 mg/mL; and resistant,  8 mg/mL) based on a
higher dosing regimen (2 g every 8 hours).5 It is a less
optimal condition that the target attainment rates for 50%
T > MIC for isolates with a cefazolin MIC of 4 mg/mL can
achieve only 42w51% at the dose of 1 g every 6 hours and
65w84% at the dose of 2 g every 8 hours. The bacteremia of
E. coli with a cefazolin MIC of 4 mg/mL was eradicated with
cefazolin of 1 g every 6 hours or 1 g every 8 hours in this
study. It is prudent to use cefazolin for the treatment of E.
coli isolates with a cefazolin MIC of 4 mg/mL when a high
drug level can be achieved in the infection site. Cefazolin
can reach a high drug concentration in the urinary tract and
nonobstructive biliary tract.21,22 Studies have shown that
following intravenous administration of cefazolin to normal
volunteers, mean serum concentrations peaked at
w188 mg/mL and were w4 mg/mL at 8 hours for a 1 g
dose.21,22 Bile levels in patients without obstructive biliary
disease can reach or exceed serum levels by up to five
times. However, bile levels of cefazolin are considerably
lower than serum levels in patients with obstructive biliary
disease.
From the viewpoint of clinical data, the conventional
dosing regimens (i.e., 1 g every 8 hours, 1 g every 6 hours,
and the reduced dose regimens for impaired renal function)
achieved clinical cure rates in 42 (98%) of 43 patients with
cefazolin MICs  8 mg/mL in this study. The previous study
of Klebsiella pneumoniae bacteremia also showed similar
results, i.e., the conventional dosing regimens of cefazolin
(1 g every 6 hours or 8 hours) achieved a clinical cure in 70
(97.2%) of 72 patients with a cefazolin MIC  1 mg/mL, in 14
(87.5%) of 16 patients with a cefazolin MIC of 2 mg/mL, and
in three (100%) of three patients with the cefazolin MICs of
4w8 mg/mL.16 Cefazolin has been used according to
breakpoints of 8 mg/mL for > 30 years.6 It is widely believed
that the conventional dosing schedule of 1 g every 8 hours
has been used with satisfactory results for decades. This
belief may be well founded for the treatment of noninva-
sive infections, especially those involving the urinary tract,
where the drug can reach a high concentration.6 It seems
effective to use cefazolin for the treatment of bacteremia
caused by Enterobacteriaceae with cefazolin MICs of
4w8 mg/mL in these two studies. This is discordant with the
intermediate and resistant breakpoints by CLSI 2011.
However, the numbers of patients in the group with the
cefazolin MICs of 4w8 mg/mL are too small to make a
conclusion in these two studies.
There were some limitations in this study. First, the
conventional dosing regimen appears effective for the
treatment of E. coli bacteremia with a cefazolin MIC 
2 mg/mL in patients who had no severe septic shock. This is
discordant with the higher dosing regimen recommended by
CLSI 2011. Determination of the conventional or higher
dosing regimen warrants further large scale clinical studies.
Second, the relatively small number in the group of cefa-
zolin MICs of 4w8 mg/mL was not sufficient to demonstrate
a significant association between cefazolin MIC and clinical
outcome, although the patients were successfully treated
with cefazolin. Third, most critically ill patients had been
Revised CLSI cefazolin breakpoints for E coli 773treated with extended-spectrum cephalosporins or carba-
penems, and they were excluded from the analysis.
Therefore, the evaluation of cefazolin efficacy in this study
focuses on the patient population of E. coli bacteremia
without severe septic shock. Fourth, Acute Physiology and
Chronic Health Evaluation (APACHE) scores were calculated
only when patients were admitted to the ICU. Most of the
patients in our study were not admitted to the ICU, so
APACHE scores were not listed in this study. Further pro-
spective comparative trials of cefazolin versus extended-
spectrum cephalosporins are also difficult to conduct due
to ethical dilemmas. Fifth, patients with malignancies and
neutropenia were excluded. Patients with malignancies
could have persistent symptoms and signs in the organs of
malignancies. Patients with immunocompromised condi-
tions could have other unexpected concurrent infections.
Patients with neutropenia could have a febrile condition
without bacteremia. All of these conditions would affect
the assessment of clinical response to antimicrobial treat-
ment. Therefore, they were excluded in many clinical
studies.23e25 Sixth, the primary sources of E. coli bacter-
emia included only urinary tract and biliary tract in this
study. This is because the most common sources of E. coli
bacteremia are urinary tract and intraabdominal infections;
the other sources of E. coli bacteremia are few.26,27
In conclusion, the microbiological data support the
revised CLSI breakpoints of cefazolin. The conventional
cefazolin dosing regimens can still achieve satisfactory
clinical cure rates for bacteremia of E. coli with a cefazolin
MIC  2 mg/mL in patients without severe septic shock.
Before the approval of the efficacy of cefazolin for the
treatment of E. coli isolates with a cefazolin MIC of 4 mg/
mL, it is prudent to use cefazolin only when a high drug
level can be achieved in the infection site, such as the
urinary tract.Conflicts of interest
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